Page last updated: 2024-12-06

nicotinamide n-oxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Nicotinamide N-oxide (NAO) is a naturally occurring metabolite of nicotinamide, a vitamin B3 derivative. It is formed by the enzymatic oxidation of nicotinamide. NAO has been implicated in various biological processes, including redox regulation, cellular signaling, and neuroprotection. Research on NAO focuses on its potential therapeutic applications, particularly in conditions related to oxidative stress and neurodegenerative diseases. NAO has been shown to possess antioxidant and anti-inflammatory properties, and its neuroprotective effects are attributed to its ability to protect neurons from oxidative damage and promote cell survival.'

Cross-References

ID SourceID
PubMed CID72661
CHEMBL ID3542327
CHEBI ID89640
SCHEMBL ID128526
MeSH IDM0113741

Synonyms (52)

Synonym
1-oxido-pyridin-1-ium-3-carboxamide
nsc168416
nsc-168416
3-pyridinecarboxamide, 1-oxide
nicotinamide n-oxide ,
nicotinamide, 1-oxide
1986-81-8
nsc30531
nsc-30531
nicotinamide 1-oxide
AA-516/30131031
nicotinamide n-oxide, >=98%
AKOS000282814
HMS1627P03
1-oxidopyridin-1-ium-3-carboxamide
ussfuvkehxdapm-uhfffaoysa-
inchi=1/c6h6n2o2/c7-6(9)5-2-1-3-8(10)4-5/h1-4h,(h2,7,9)
N0669
nicotinamide-n-oxide
1-oxy-nicotinamide
oxynicotinamide
nicotinamide n1-oxide
6uy6qxj2dp ,
3-carbamoylpyridin-1-ium-1-olate
FT-0633953
niacinamide n-oxide
pyridine-3-carboxamide 1-oxide
AB00172193-03
SCHEMBL128526
1-oxynicotinamide
DTXSID70173614
chebi:89640 ,
CHEMBL3542327
nicotinamide-d4 n-oxide
J-512155
3-carbamoylpyridine 1-oxide
mfcd00006202
1-oxide-nicotinamide
1-oxide-(8ci)-nicotinamide
1-oxide-3-pyridinecarboxamide
HY-101407
CS-6294
NCGC00321171-01
FT-0672697
Q27161835
AS-40816
3-(aminocarbonyl)pyridinium-1-olate
CCG-266146
3-pyridinecarboxamide, oxynicotinamide
EN300-7322133
SY025187
nicotinamide n inverted exclamation mark -oxide

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"Full pharmacokinetic profiles of nicotinamide concentrations in plasma were analyzed repeatedly in 15 patients to determine the inter- and intra-patient variability in peak plasma concentrations and the optimum times for administering nicotinamide as a radiosensitizer."( Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.
Bernier, J; Bieri, S; Bolla, M; Denekamp, J; Dennis, MF; Hagen, F; Kocagöncü, O; Rojas, A; Stratford, MR, 1998
)
0.3
" The peak plasma concentration was achieved at 1 h in only 54% of the pharmacokinetic profiles, but at this time 92% of the profiles had already exceeded the target concentration of 700 nmol/ml, the level required in the mouse for tumour radiosensitization."( Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.
Bernier, J; Bieri, S; Bolla, M; Denekamp, J; Dennis, MF; Hagen, F; Kocagöncü, O; Rojas, A; Stratford, MR, 1998
)
0.3

Dosage Studied

ExcerptRelevanceReference
" Twelve healthy males were enrolled in an open-label, dose-rate escalation study and received 2000 mg niacin at 3 different dosing rates."( Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites.
Adams, MH; Cefali, EA; González, MA; Leu, JH; Menon, RM; Tolbert, DS, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1653801Substrate activity at human mARC1 expressed in Escherichia coli assessed as turnover rates at 3 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by LC-MS analysis based assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID1653796Substrate activity at human mARC2 expressed in Escherichia coli assessed as turnover rates at 3 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by UV-Visible spectroscopy based NADH assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID1653806Substrate activity at human mARC2 expressed in Escherichia coli assessed as turnover rates at 3 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by LC-MS analysis based assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID1653791Substrate activity at human mARC1 expressed in Escherichia coli assessed as turnover rates at 3 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by UV-Visible spectroscopy based NADH assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (24.00)18.7374
1990's3 (12.00)18.2507
2000's7 (28.00)29.6817
2010's7 (28.00)24.3611
2020's2 (8.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.89 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (11.54%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (88.46%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]